Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001241415 | SCV001414429 | uncertain significance | not provided | 2022-10-05 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 906 of the MYO7A protein (p.Arg906His). This variant is present in population databases (no rsID available, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with MYO7A-related conditions. ClinVar contains an entry for this variant (Variation ID: 966679). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MYO7A protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002484324 | SCV002792210 | uncertain significance | Autosomal dominant nonsyndromic hearing loss 11; Autosomal recessive nonsyndromic hearing loss 2; Usher syndrome type 1 | 2021-07-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004960627 | SCV005456107 | uncertain significance | Inborn genetic diseases | 2024-08-01 | criteria provided, single submitter | clinical testing | The c.2717G>A (p.R906H) alteration is located in exon 23 (coding exon 22) of the MYO7A gene. This alteration results from a G to A substitution at nucleotide position 2717, causing the arginine (R) at amino acid position 906 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001835102 | SCV002086637 | uncertain significance | Usher syndrome type 1B | 2021-03-09 | no assertion criteria provided | clinical testing |